據報俄羅斯或成中國境外首個註冊康希諾(06185.HK)疫苗國家
《彭博通訊社》報道,康希諾生物(06185.HK)新冠疫苗的俄羅斯合作夥伴Petrovax Pharm希望俄國當局儘快註冊該疫苗,或成該款疫苗首次在中國境外獲得接種批准。Petrovax由俄羅斯首富Vladimir Potanin持有,公司醫療部門負責人Nikolay Dodonov表示,所有註冊流程都已完成,預計數天內就將獲得註冊認證。
康希諾疫苗目前在進行三期試驗,並在中國獲得了緊急使用授權,但至今疫苗接種僅用於中國軍人。Dodonov表示,去年8月Petrovax獲得康希諾新冠疫苗在當地進行三期試驗的許可,11月申請註冊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.